[go: up one dir, main page]

CL2017002745A1 - Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas - Google Patents

Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas

Info

Publication number
CL2017002745A1
CL2017002745A1 CL2017002745A CL2017002745A CL2017002745A1 CL 2017002745 A1 CL2017002745 A1 CL 2017002745A1 CL 2017002745 A CL2017002745 A CL 2017002745A CL 2017002745 A CL2017002745 A CL 2017002745A CL 2017002745 A1 CL2017002745 A1 CL 2017002745A1
Authority
CL
Chile
Prior art keywords
sulfonimidoylpurinone
prophylaxis
derivatives
treatment
viral infections
Prior art date
Application number
CL2017002745A
Other languages
English (en)
Inventor
Hongying Yun
Xiufang Zheng
Chungen Liang
Kun Miao
Jianping Wang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2017002745A1 publication Critical patent/CL2017002745A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>La presente invención se refiere a compuestos de fórmula (I), en la que R 1 , R 2 y R 3 son como se han descrito en el presente documento, y sus profármacos o sales, enantiómeros o diastereómeros farmacéuticamente aceptables de los mismos, y composiciones que incluyen los compuestos y métodos para usar los compuestos.</p>
CL2017002745A 2015-05-08 2017-10-30 Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas CL2017002745A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2015078507 2015-05-08
CN2016078785 2016-04-08

Publications (1)

Publication Number Publication Date
CL2017002745A1 true CL2017002745A1 (es) 2018-05-18

Family

ID=55910966

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002745A CL2017002745A1 (es) 2015-05-08 2017-10-30 Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas

Country Status (32)

Country Link
US (3) US9708325B2 (es)
EP (1) EP3294740B1 (es)
JP (1) JP6738352B2 (es)
KR (1) KR102690131B1 (es)
CN (1) CN107580596B (es)
AR (1) AR104528A1 (es)
AU (3) AU2016260683B2 (es)
BR (1) BR112017023959B1 (es)
CA (1) CA2982704C (es)
CL (1) CL2017002745A1 (es)
CO (1) CO2017009994A2 (es)
CR (1) CR20170496A (es)
DK (1) DK3294740T3 (es)
ES (1) ES2753777T3 (es)
HR (1) HRP20191942T1 (es)
HU (1) HUE045906T2 (es)
IL (2) IL254947B (es)
LT (1) LT3294740T (es)
MX (2) MX376761B (es)
MY (1) MY182353A (es)
NZ (2) NZ735648A (es)
PE (1) PE20171620A1 (es)
PH (1) PH12017502009A1 (es)
PL (1) PL3294740T3 (es)
PT (1) PT3294740T (es)
RS (1) RS59435B1 (es)
RU (1) RU2745269C2 (es)
SG (1) SG10202108841YA (es)
SI (1) SI3294740T1 (es)
TW (2) TWI706954B (es)
UA (1) UA120450C2 (es)
WO (1) WO2016180695A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017023959B1 (pt) 2015-05-08 2023-05-02 F. Hoffmann-La Roche Ag Novos compostos de sulfonimidoilpurinona e derivados para o tratamento e profilaxia de infecção por vírus
RU2751349C2 (ru) * 2016-08-29 2021-07-13 Ф. Хоффманн-Ля Рош Аг 7-замещенные сульфонимидоилпуриноны для лечения и профилактики вирусной инфекции
KR102497701B1 (ko) * 2016-09-13 2023-02-09 에프. 호프만-라 로슈 아게 Tlr7 작용제 및 hbv 캡시드 조립 억제제의 병용 치료
EP3752505B1 (en) 2018-02-12 2023-01-11 F. Hoffmann-La Roche AG Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection
WO2019166432A1 (en) * 2018-02-28 2019-09-06 F. Hoffmann-La Roche Ag 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
CN111072667A (zh) * 2018-10-22 2020-04-28 罗欣药业(上海)有限公司 五元或六元杂环并嘧啶类化合物及其用途
JP7695885B2 (ja) * 2019-02-12 2025-06-19 アンブルックス，インコーポレイテッド 抗体－ｔｌｒアゴニストコンジュゲートを含有する組成物、その方法、及び使用
CN114450280B (zh) 2019-09-20 2025-02-25 先正达农作物保护股份公司 具有含硫和亚砜亚胺取代基的杀有害生物活性杂环衍生物
US20230140430A1 (en) * 2020-01-27 2023-05-04 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
EP4097105A1 (en) * 2020-01-27 2022-12-07 Bristol-Myers Squibb Company 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
WO2024013205A1 (en) 2022-07-14 2024-01-18 F. Hoffmann-La Roche Ag Phosphorylpurinone compounds for the treatment of cancer
CN118724963A (zh) * 2023-03-30 2024-10-01 浙江养生堂天然药物研究所有限公司 含磷或含硫的大环化合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4189048B2 (ja) * 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
MX2007013780A (es) 2005-05-04 2008-02-05 Pfizer Ltd Derivados 2 amido-6-amino-8-oxo purina como moduladores del receptor como tipo peaje (toll) para el tratamiento del cancer y las infecciones virales tal como la hepatitis c.
CN101239980B (zh) 2008-02-18 2011-06-22 靳广毅 免疫受体调节剂偶联体前体和偶联体及其应用
CA2745295C (en) * 2008-12-09 2017-01-10 Gilead Sciences, Inc. Modulators of toll-like receptors
WO2011079016A1 (en) 2009-12-22 2011-06-30 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
TWI555737B (zh) * 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
PT2776439T (pt) * 2011-11-09 2018-11-02 Janssen Sciences Ireland Uc Derivados de purina para o tratamento de infeções virais
CA2902837C (en) 2013-03-29 2021-09-07 Janssen Sciences Ireland Uc Macrocyclic deaza-purinones for the treatment of viral infections
HUE054672T2 (hu) 2014-08-15 2021-09-28 Chia Tai Tianqing Pharmaceutical Group Co Ltd TLR7 agonistaként alkalmazott pirrolopirimidin vegyületek
BR112017023959B1 (pt) * 2015-05-08 2023-05-02 F. Hoffmann-La Roche Ag Novos compostos de sulfonimidoilpurinona e derivados para o tratamento e profilaxia de infecção por vírus
RU2751349C2 (ru) * 2016-08-29 2021-07-13 Ф. Хоффманн-Ля Рош Аг 7-замещенные сульфонимидоилпуриноны для лечения и профилактики вирусной инфекции

Also Published As

Publication number Publication date
CN107580596A (zh) 2018-01-12
US10399983B2 (en) 2019-09-03
IL254947A0 (en) 2017-12-31
PH12017502009A1 (en) 2018-03-26
AU2022204666A1 (en) 2022-07-21
BR112017023959A2 (pt) 2018-07-17
CO2017009994A2 (es) 2018-02-20
EP3294740B1 (en) 2019-09-04
RS59435B1 (sr) 2019-11-29
MX2017014033A (es) 2018-03-01
MY182353A (en) 2021-01-20
CA2982704C (en) 2023-10-24
TWI706954B (zh) 2020-10-11
PT3294740T (pt) 2019-10-29
RU2017142577A (ru) 2019-06-10
US11242345B2 (en) 2022-02-08
MX393198B (es) 2025-03-19
ES2753777T3 (es) 2020-04-14
WO2016180695A1 (en) 2016-11-17
SG10202108841YA (en) 2021-09-29
IL254947B (en) 2021-02-28
NZ735648A (en) 2023-06-30
TW201716410A (zh) 2017-05-16
AU2016260683A1 (en) 2017-10-12
IL280769B1 (en) 2023-03-01
NZ775222A (en) 2024-09-27
IL280769B2 (en) 2023-07-01
UA120450C2 (uk) 2019-12-10
LT3294740T (lt) 2019-11-25
PL3294740T3 (pl) 2020-03-31
CR20170496A (es) 2017-12-05
PE20171620A1 (es) 2017-11-02
IL280769A (en) 2021-04-29
AR104528A1 (es) 2017-07-26
HRP20191942T1 (hr) 2020-01-10
HK1247925A1 (zh) 2018-10-05
TWI768467B (zh) 2022-06-21
RU2017142577A3 (es) 2019-10-31
US20200109144A1 (en) 2020-04-09
BR112017023959B1 (pt) 2023-05-02
TW202108584A (zh) 2021-03-01
SI3294740T1 (sl) 2019-12-31
AU2020256348B2 (en) 2022-06-16
AU2020256348A1 (en) 2020-11-12
KR102690131B1 (ko) 2024-07-31
JP2018515509A (ja) 2018-06-14
KR20180003612A (ko) 2018-01-09
US20170275286A1 (en) 2017-09-28
MX2020010949A (es) 2022-06-16
MX376761B (es) 2025-03-07
JP6738352B2 (ja) 2020-08-12
CN107580596B (zh) 2020-07-14
CA2982704A1 (en) 2016-11-17
EP3294740A1 (en) 2018-03-21
US9708325B2 (en) 2017-07-18
HUE045906T2 (hu) 2020-01-28
RU2745269C2 (ru) 2021-03-22
US20160326177A1 (en) 2016-11-10
AU2016260683B2 (en) 2020-10-29
DK3294740T3 (da) 2019-11-04

Similar Documents

Publication Publication Date Title
CL2017002745A1 (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas
CO2019000932A2 (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica.
CR20170237A (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
CO2017007355A2 (es) Compuestos derivados de pirazincarbozamida y de pirazincarboxilato para el tratamiento de la infección por el virus de hepatitis b
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
MX2023001876A (es) Derivados de rapamicina.
CO2018000660A2 (es) Compuestos derivados del (3β)-cholest-5-en-3-alquil-3-ol y (3β)-cholest-3-alquil-3-ol
MX2017001862A (es) Nuevas piridazonas y triazinonas para el tratamiento y la profilaxis de infeccion por virus de hepatitis b.
UY36170A (es) Compuestos de dihidroisoquinolinona sustituida
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
DOP2016000299A (es) Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y su uso como inhibidores ido1
MX2018005890A (es) Composiciones para tratar atrofia muscular espinal.
UY36677A (es) Compuestos tricíclicos como agentes antineoplásicos
MX2019003026A (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2.
GT201400167A (es) Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2
CL2020002139A1 (es) Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevención del cáncer de hígado.
CO2018004213A2 (es) Compuesto piranodipiridínico
CO2017009989A2 (es) Piridopirimidinonas y utilización de las mismas como moduladores de receptores de nmda
MX2017003788A (es) Derivados de nucleósidos sustituidos con 4´-vinilo como inhibidores de la replicación del arn del virus respiratorio sincitial.
EA201990238A1 (ru) ФОСФОРСОДЕРЖАЩИЕ ПРОЛЕКАРСТВА СТИМУЛЯТОРОВ sGC
GT201600232A (es) Derivados de diheterociclo enlazado a cicloalquilo
CO2017003225A2 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos
NI201600171A (es) Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1
CR20160532A (es) Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1